{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"2.1","value":"1.28"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"4.6","value":"2.12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"TTR was defined as time between the date of administration of the first dose of the study drug and the date of first documentation PR or CR based on independent review of Efficacy and Safety Evaluation Committee. PR or CR were assessed according to modified response criteria based on the revised response criteria for malignant lymphoma (Cheson, 2007), skin lesion and peripheral blood disease were assessed according to clinical end points and response criteria in mycosis fungoides and Sezary syndrome (Olsen, 2011). TTR was only conducted among responders who had experienced CR or PR. CR: Disappearance of all evidence of disease; PR: Regression of measurable disease and no new sites.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed or refractory PTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL: E7777 9 mcg/kg/Day"},{"description":"Participants with CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG001","title":"CTCL: E7777 9 mcg/kg/Day"},{"description":"Participant with extranodal NK/T-cell lymphoma received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG002","title":"Other: E7777 9 mcg/kg/Day"}],"paramType":"MEDIAN","populationDescription":"The FAS was defined as a group of participants who received at least 1 dose of the study drug. Here \"overall number of participants analyzed\" signifies responded participants.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until date of the first documentation of PR or CR or death due to any cause (whichever occurred first) up to approximately 3 years 1 month","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}